Blind sampling: difference between revisions
Diff·revision 18 → 19·13:52, 7 Jul 2025
Difference between revision 18 and revision 19 of Blind sampling. 6 lines changed; the page grew by 558 bytes.
| Revision 18 — 19:17, 17 Jun 2025 PurityClaimPia (talk) state the method the reporting service uses, since it is not the only one available 7,309 bytes ±0 | Revision 19 — 13:52, 7 Jul 2025 StubSorterBot (talk) bot: update parent category chain 7,867 bytes +558 | ||
|---|---|---|---|
| 50 | '''Every published aggregate is labelled at each point of use''' with its sample size, its collection period and the words that make its provenance visible — self-reported, self-selected. Labelling once at the head of a section is not enough, because paragraphs are split and reordered and the label does not travel with them.{{r|reports}} | 50 | '''Every published aggregate is labelled at each point of use''' with its sample size, its collection period and the words that make its provenance visible — self-reported, self-selected. Labelling once at the head of a section is not enough, because paragraphs are split and reordered and the label does not travel with them.{{r|reports}} |
| 51 | 51 | ||
| + | 52 | '''No aggregate is presented as a ranking.''' A tally of submissions is a measurement of who submitted, and the difference between two communities' figures for one organisation is evidence about the two communities. PeptidePedia publishes no score and maintains no league table, and the reason is on this page rather than in a style rule. | |
| + | 53 | ||
| 52 | == References == | 54 | == References == |
| 53 | {{reflist}} | 55 | {{reflist}} |
| ⋮ | ⋮ | ||
| 56 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Treats sampling as a quality-system responsibility distinct from the analysis performed on the sample.</ref> | 58 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. Treats sampling as a quality-system responsibility distinct from the analysis performed on the sample.</ref> |
| 57 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 59 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 60 | ||
| + | 61 | == Further reading == | |
| + | 62 | * [[Project:Sourcing guidelines]] — the labelling this wiki requires on any community-derived figure. | |
| + | 63 | * [[Project:Neutral point of view]] — why a tally may be reported and may not be ranked. | |
| 58 | 64 | ||
| 59 | == See also == | 65 | == See also == |